Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cascade Prodrug Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The current prosecution activity involves a distinct examiner and a distinct art unit, indicating a streamlined interaction with the patent office for this portfolio. This concentration within a single art unit suggests that the company's active patent filings are technically related and are being evaluated by a consistent set of examination standards.
The busiest examiner, DAHLIN, HEATHER RAQUEL, is currently managing the 1 busiest examiner pending action. Because this examiner is the sole point of contact for the company's pending matters, understanding their specific examination history and preferences is critical for advancing the application. The applicant's strategy should be highly tailored to the specific technical objections or legal requirements typically emphasized by DAHLIN, HEATHER RAQUEL in the biotechnology sector.
With a distinct examiner involved, the company can focus its resources on a single prosecution track. This lack of examiner diversity in the current portfolio means that the immediate future of the company's patent rights in Biotechnology & Pharmaceuticals depends on the outcome of the pending office action. Efficiently addressing the examiner's concerns will be the most direct way to move the portfolio toward allowance and reduce the current pending workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAHLIN, HEATHER RAQUEL | 1 | 41.1% | +47.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18269526 | COMBINATION THERAPY WITH A VINCA ALKALOID N-OXIDE AND AN IMMUNE CHECKPOINT INHIBITOR | DAHLIN, HEATHER RAQUEL | 19d |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18269526 | COMBINATION THERAPY WITH A VINCA ALKALOID N-OXIDE AND AN IMMUNE CHECKPOINT INHIBITOR | DAHLIN, HEATHER RAQUEL | 1629 | §103Other | Final Rejection | 19d | Pending | Jun 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial